论文部分内容阅读
目的总结分析小儿支原体肺炎发病年龄分布,探讨阿奇霉素联合克林霉素治疗此病的应用价值。方法回顾性分析2012年1月至2013年10月钦州市钦北区妇幼保健院收治的108例小儿支原体肺炎患儿的发病情况与年龄关系,观察阿奇霉素联合克林霉素治疗(研究组)及单用克林霉素治疗(对照组)的临床效果。结果本研究108例患儿中0~3岁20例,占18.5%;3~7岁50例,占46.3%;7~10岁28例,占25.9%;10岁以上10例,占9.3%。研究组治疗总有效率为98.1%,显著高于对照组的72.2%,差异有统计学意义(P<0.05)。两组治疗前CD4+、CD4+/CD8+比较差异未见统计学意义(P>0.05),治疗后CD4+、CD4+/CD8+均明显升高,以研究组升高最多,与治疗前比较差异均有统计学意义(P<0.05)。研究组治疗后一氧化氮、肿瘤坏死因子-α、超敏C-反应蛋白水平与对照组比较均明显下降(P<0.05)。对照组不良反应发生率为20.4%,研究组为1.9%。结论小儿支原体肺炎发病率比较高的年龄阶段为3~7岁。阿奇霉素联合克林霉素治疗小儿支原体肺炎临床疗效显著,不良反应发生率低,可作为临床治疗此病的首选用药。
Objective To summarize and analyze the age distribution of infantile mycoplasma pneumonia and to explore the value of azithromycin combined with clindamycin in the treatment of this disease. Methods A retrospective analysis was made on the relationship between the incidence and the age of 108 cases of children with mycoplasma pneumonia admitted to Qinbei District Maternal and Child Health Hospital from January 2012 to October 2013. The azithromycin combined with clindamycin treatment (study group) and Clinical effect of clindamycin alone (control group). Results Of the 108 children aged 0-3 years, 20 (18.5%), 50 (3-7 years), 46.3% (28-7 years), 25.9% (7-10 years), 9.3% (10-10 years old) . The total effective rate of the study group was 98.1%, which was significantly higher than that of the control group (72.2%), the difference was statistically significant (P <0.05). There was no significant difference in CD4 +, CD4 + / CD8 + between the two groups before treatment (P> 0.05), CD4 + and CD4 + / CD8 + were significantly increased after treatment, with the highest increase in the study group, and statistical difference Significance (P <0.05). After treatment, the levels of nitric oxide, tumor necrosis factor-α and high sensitivity C-reactive protein in study group were significantly lower than those in control group (P <0.05). The incidence of adverse reactions was 20.4% in the control group and 1.9% in the study group. Conclusion The incidence of mycoplasma pneumonia is relatively high in children aged 3 to 7 years old. Azithromycin combined with clindamycin in children with mycoplasma pneumonia clinical significant effect, the incidence of adverse reactions is low, can be used as the first choice of clinical treatment of the disease.